Activity Details

Accredited By

Target Audience

This activity is designed to meet the educational needs of oncology and pathology clinicians involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

• Assess the potential role of novel therapies directed against TROP2 and other emerging targets in the management of non-small cell lung cancer (NSCLC) 
• Identify the potential impact of HER2-/3-directed therapies on the current NSCLC treatment algorithm

Activity Description

The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of targeted agents. This educational activity is designed to provide a synopsis of novel targets and therapies. Jacob Sands, MD, a thoracic medical oncologist, will provide the latest data for newly approved and investigational MET and RET inhibitors, as well as the latest evidence for drug-antibody conjugates directed towards HER2, HER3, TROP2, and B7-H3.

Statement of Commercial Support

The rapid development of novel targets and therapies for NSCLC exemplifies the precision medicine approach in clinical oncology. The first MET and RET inhibitors have recently joined the ever-expanding treatment armamentarium, and others are currently in development. Data is emerging for antibody-drug conjugates designed to target HER2, HER3, TROP2, and B7-H3. Expert guidance is needed to stay abreast of this continually evolving and increasingly complex therapeutic landscape in order to provide optimal patient care and potentially enroll eligible patients into clinical trials.

Agenda

1. 1. The importance of broad molecular profiling in NSCLC.
2. 2. Recently presented data for currently approved and investigational MET and RET inhibitors.
3. 3. Recently presented data for drug-antibody conjugates targeting HER2, HER3, TROP2, and B7-H3.
4. 4. Summary

Faculty

Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Jacob Sands, MD received his MD from the University of Cincinnati in 2005. He completed both residency in internal medicine and fellowship training in hematology/oncology at the University of California, Davis. He joined Dana-Farber Cancer Institute in 2017 where he treats patients with lung cancer and leads clinical research, including an NCI-sponsored study evaluating incorporation of checkpoint inhibitor into adjuvant therapy for non-small cell lung cancer. Dr. Sands leads the small cell lung cancer program at Dana-Farber Cancer Institute and sits on the NCCN guidelines committee for small cell lung cancer as well as the guidelines committee for lung screening. Dr. Sands is a member of the IASLC Screening & Early Detection Committee, a scientific advisory board member of the GO2 Foundation for Lung Cancer, a media spokesperson for the American Lung Association, and Treasurer of the Rescue Lung Rescue Life Society.

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.  

Jacob Sands, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Medtronic, Pharma Mar (Consulting Fees); Merck (Research).  

Planners and Managers  
The Postgraduate Institute for Medicine planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose.  

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

There is no fee for this educational activity. 

During the period July 31, 2020 through July 30, 2021, participants must:

1. 1. Read the learning objectives and disclosures
2. 2. Study the educational activity
3. 3. Complete the evaluation form

Select the desired certificate and click on Submit. Click on Download Certificate and print the certificate for your records. 

Accreditation Support 
Please contact Postgraduate Institute for Medicine Continuing Medical Education Department at inquiries@pimed.com or by calling 303-799-1930 

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Disclosure of Unlabeled Use 
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer 
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

Contact Information for Questions about the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

Activity Details

Accredited By

Target Audience

This activity is designed to meet the educational needs of oncology and pathology clinicians involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

• Assess the potential role of novel therapies directed against TROP2 and other emerging targets in the management of non-small cell lung cancer (NSCLC) 
• Identify the potential impact of HER2-/3-directed therapies on the current NSCLC treatment algorithm

Activity Description

The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of targeted agents. This educational activity is designed to provide a synopsis of novel targets and therapies. Jacob Sands, MD, a thoracic medical oncologist, will provide the latest data for newly approved and investigational MET and RET inhibitors, as well as the latest evidence for drug-antibody conjugates directed towards HER2, HER3, TROP2, and B7-H3.

Statement of Commercial Support

The rapid development of novel targets and therapies for NSCLC exemplifies the precision medicine approach in clinical oncology. The first MET and RET inhibitors have recently joined the ever-expanding treatment armamentarium, and others are currently in development. Data is emerging for antibody-drug conjugates designed to target HER2, HER3, TROP2, and B7-H3. Expert guidance is needed to stay abreast of this continually evolving and increasingly complex therapeutic landscape in order to provide optimal patient care and potentially enroll eligible patients into clinical trials.

Agenda

1. 1. The importance of broad molecular profiling in NSCLC.
2. 2. Recently presented data for currently approved and investigational MET and RET inhibitors.
3. 3. Recently presented data for drug-antibody conjugates targeting HER2, HER3, TROP2, and B7-H3.
4. 4. Summary

Faculty

Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Jacob Sands, MD received his MD from the University of Cincinnati in 2005. He completed both residency in internal medicine and fellowship training in hematology/oncology at the University of California, Davis. He joined Dana-Farber Cancer Institute in 2017 where he treats patients with lung cancer and leads clinical research, including an NCI-sponsored study evaluating incorporation of checkpoint inhibitor into adjuvant therapy for non-small cell lung cancer. Dr. Sands leads the small cell lung cancer program at Dana-Farber Cancer Institute and sits on the NCCN guidelines committee for small cell lung cancer as well as the guidelines committee for lung screening. Dr. Sands is a member of the IASLC Screening & Early Detection Committee, a scientific advisory board member of the GO2 Foundation for Lung Cancer, a media spokesperson for the American Lung Association, and Treasurer of the Rescue Lung Rescue Life Society.

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.  

Jacob Sands, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Medtronic, Pharma Mar (Consulting Fees); Merck (Research).  

Planners and Managers  
The Postgraduate Institute for Medicine planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose.  

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

There is no fee for this educational activity. 

During the period July 31, 2020 through July 30, 2021, participants must:

1. 1. Read the learning objectives and disclosures
2. 2. Study the educational activity
3. 3. Complete the evaluation form

Select the desired certificate and click on Submit. Click on Download Certificate and print the certificate for your records. 

Accreditation Support 
Please contact Postgraduate Institute for Medicine Continuing Medical Education Department at inquiries@pimed.com or by calling 303-799-1930 

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Disclosure of Unlabeled Use 
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer 
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

Contact Information for Questions about the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

Activity Details

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.

Learning Objectives

After completing this program, participants should be able to:

• Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
• Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
• Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Jonathon B. Cohen, MD, MS
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA

Conflict of Interest Policy/Disclosure Statement

Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.

Learning Objectives

After completing this program, participants should be able to:

• Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
• Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
• Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Jonathon B. Cohen, MD, MS
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA

Conflict of Interest Policy/Disclosure Statement

Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

• Assess the efficacy and safety of PARP inhibitors or their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
• Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
• Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
• Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer

Activity Description

This activity will provide expert guidance regarding the use of currently-available therapies and companion diagnostics and will help clinicians plan for the optimal integration of new indications and combinations into practice when they become available.

Statement of Educational Need

Considering the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications and combinations into practice when they become available, in consideration of patient needs and preferences.

Agenda

• Currently Available Systemic and Maintenance Therapies and Emerging Combinations for the Treatment of Ovarian Cancer
• Integrating Genetic Testing Into Clinical Practice
• Real-World Use of Poly ADP Ribose Polymerase Inhibitors (PARPi): Case-Based Discussion
• Summary

Faculty

Thomas Herzog, MD
Deputy Director, University of Cincinnati Cancer Institute
Paul & Carolyn Flory Professor, Vice-Chair of Quality & Safety
Department of Obstetrics & Gynecology
University of Cincinnati
Cincinnati, Ohio

Disclosures
Advisory Boards: AstraZeneca, Caris Life Sciences, Clovis Oncology, F. Hoffman-La Roche, Tesaro, Inc.

Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through April 18, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, and Tesaro, a GSK Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

Activity Details

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

• Assess the efficacy and safety of PARP inhibitors or their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
• Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
• Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
• Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer

Activity Description

This activity will provide expert guidance regarding the use of currently-available therapies and companion diagnostics and will help clinicians plan for the optimal integration of new indications and combinations into practice when they become available.

Statement of Educational Need

Considering the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications and combinations into practice when they become available, in consideration of patient needs and preferences.

Agenda

• Currently Available Systemic and Maintenance Therapies and Emerging Combinations for the Treatment of Ovarian Cancer
• Integrating Genetic Testing Into Clinical Practice
• Real-World Use of Poly ADP Ribose Polymerase Inhibitors (PARPi): Case-Based Discussion
• Summary

Faculty

Thomas Herzog, MD
Deputy Director, University of Cincinnati Cancer Institute
Paul & Carolyn Flory Professor, Vice-Chair of Quality & Safety
Department of Obstetrics & Gynecology
University of Cincinnati
Cincinnati, Ohio

Disclosures
Advisory Boards: AstraZeneca, Caris Life Sciences, Clovis Oncology, F. Hoffman-La Roche, Tesaro, Inc.

Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through April 18, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, and Tesaro, a GSK Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

Activity Details

Accredited By

Target Audience

This activity is intended for oncologists, pulmonologists, pathologists, advanced practice nurses, nurse practitioners, and PAs who manage patients with SCLC.

Learning Objectives

• Describe the role of the immune system in tumor pathogenesis and how immunotherapy can be utilized to modulate the anti-tumor immune response
• Evaluate current and emerging immunotherapies for the management of small cell lung cancer (SCLC) on the basis of clinical trial safety and efficacy data
• Incorporate immunotherapy into the management of patients with SCLC where appropriate
• Identify and manage immune-related adverse events associated with checkpoint inhibitors

Activity Description

In this interactive panel discussion, oncology experts and a patient with SCLC discuss recent advances in the use of immunotherapy for SCLC management. Experts present the latest efficacy data supporting the use of immune checkpoint inhibitors and strategies for managing treatment-related adverse events. An experienced patient with SCLC provides his unique perspective on treatment administration, education, and expectations. The panel concludes by addressing the personalized selection of patients with SCLC who may benefit from immunotherapy.

Statement of Educational Need

Small cell lung cancer is an aggressive form of lung cancer that is historically associated with limited treatment options and low survival rates. However, in the last few years immunotherapies have emerged as effective treatment options for SCLC, particularly in people with extensive-stage disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the efficacy, safety, and tolerability of immunotherapies, the rationale for use in SCLC, and how to incorporate these treatments into SCLC management.

Agenda

This activity will address the following topics:

• Role of the immune system in tumor pathogenesis
• Rationale for immunotherapy in SCLC
• Brief overview of the mechanism of action of immunotherapy
• Evidence on the safety and efficacy of approved and emerging immune checkpoint inhibitors
• Recognizing and managing immune-mediated adverse reactions associated with immunotherapy
• Description of ongoing and planned clinical trials of immunotherapy for SCLC
• Identifying patients who may benefit from immunotherapy

Faculty

Hossein Borghaei, DO, MS (Chair)
Chief, Thoracic Oncology
Professor, Department of Hematology and Oncology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M. Dunn Chair in Thoracic Malignancies
Fox Chase Cancer Center
Philadelphia, PA

Hossein Borghaei, DO, MS, is the chief of Thoracic Oncology and a professor in the Department of Hematology/Oncology at the Fox Chase Cancer Center in Philadelphia, PA. He earned his medical degree at Philadelphia College of Osteopathic Medicine and completed his residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer. Dr. Borghaei is board certified in medical oncology.

Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic. He served as the PI of a Phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting.

Dr. Borghaei is a member of the thoracic core committee at Eastern Cooperative Oncology Group (ECOG) and, until recently, was a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer panel. He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. Dr. Borghaei is a long-standing member of ASCO, AACR, and NCCN and ECOG thoracic committees. Dr. Borghaei has published in many peer-reviewed publications, including The New England Journal of Medicine, The Lancet Oncology, Lung Cancer, and the Journal of Thoracic Oncology.

Hossein Borghaei, DO, MS, has affiliations with AbbVie, Amgen, AstraZeneca, Axiom, Boehringer Ingelheim, BioNTech, Bristol-Myers Squibb, Cantargia AB, Celgene, Daiichi, EMD-Serono, Genentech, Genmab, GLG, Huya Bio, Lilly, Merck, Novartis, Pfizer, PharmaMar, Regeneron, Takeda (Consultant); Merck/Celgene, Millennium, Bristol-Myers Squibb/Lilly (To Institution) (Contracted Research); Incyte, Takeda, U of Pennsylvania (Data Safety Monitoring Board); Rgenix, Sonnetbio (Stock).

Taofeek K. Owonikoko, MD, PhD, MSCR
Professor and Vice-Chair, Faculty Development
Department of Hematology and Medical Oncology
Chair, Thoracic Malignancies Working Group
Director of Thoracic Oncology
Co-Leader, Discovery & Developmental Therapeutics Program
Winship Cancer Institute
Emory University
Druid Hills, GA

Taofeek K. Owonikoko, MD, PhD, MSCR, is Professor and Vice-Chair for Faculty Development in the Department of Hematology and Medical Oncology and Co-Leader of the Discovery & Developmental Therapeutics Program at the Winship Cancer Institute of Emory University. Dr. Owonikoko received his primary medical training at the Obafemi Awolowo University in Ile-Ife, Nigeria. He completed his residency in anatomic pathology at the Lagos University Teaching Hospital and later proceeded to Dusseldorf, Germany for further training in anatomic pathology at the Heinrich Heine University. He received his PhD degree in anatomic pathology from the Heinrich Heine University, after which he proceeded to the Johns Hopkins University in Baltimore for postdoctoral training in molecular imaging. Dr. Owonikoko is board certified in medical oncology.

Dr. Owonikoko is a world-renowned expert in the treatment of lung cancer. He is particularly interested in advancing the care of and improving the outcomes for small cell lung cancer (SCLC). He leads an active clinical and research program at the Winship Cancer Institute at Emory University looking at new treatment strategies for patients through clinical trials and translational research work in the lab. Dr. Owonikoko has received awards on his leadership, including the IASLC Heine H. Hansen Lectureship Award and the NCI Cancer Clinical Investigator Team Leadership Award. He has also been published in many peer-reviewed journals, including the Journal of Thoracic Oncology, The Cancer Journal, Clinical Cancer Research, and Molecular Oncology.

Taofeek Owonikoko, MD, PhD, MSCR, has affiliations with AbbVie, Amgen, ARMO BioScience, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, EMD Serono, G1 Therapeutics, Heron Pharmaceutical, Lilly, MedImmune, Merck, Novartis, Sandoz, Seattle Genetics, PharmaMar, Takeda, XCovery (Consulting/Advisory Board); AbbVie, Aeglea Biotherapeutics, Amgen, Astellas Pharma, AstraZenea/MedImmune, Bayer, Bristol-Myers Squibb, Corvus Pharmaceuticals, Fujifilm, G1 Therapeutics, Incyte, Loxo/Lilly, Merck, Novartis, Pfizer, Regeneron, StemCentRx, United Therapeutics, EMD Serono, Roche/Genentech (IRC/DSMB); Cambium Oncology (Stock).

Kristen Kreamer, CRNP, AOCNP, APRN, BC
Nurse Practitioner, Thoracic and Head and Neck Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Kristen Kreamer, CRNP, AOCNP, APRN, BC, is a medical oncology nurse practitioner at Fox Chase Cancer Center in Philadelphia, PA. Ms. Kreamer earned her MS in nursing from Yale University in New Haven, CT, and worked as a clinical nurse specialist for 12 years before completing a post-masters certification as an oncology nurse practitioner at the University of Pennsylvania in Philadelphia, PA.

Ms. Kreamer’s practice includes patients with lung and head and neck malignancies and she also works with the Lung Cancer Screening and Tobacco Treatment programs at Fox Chase. She is a member of the Oncology Nursing Society, the Advanced Practice Society for Hematology/Oncology and Sigma Theta Tau International. Ms. Kreamer has been published in The Journal for Advanced Practitioners in Oncology and other peer-reviewed publications.

Kristen Kreamer, CRNP, AOCNP, APRN, BC, has affiliations with AstraZeneca (Speakers Bureau).

Cedric White (Patient)
Cedric White has nothing to disclose.

Conflict of Interest Policy/Disclosure Statement

AKH planners and reviewers have no financial relationships to disclose.
RMEI Medical Education, LLC planners and managers have no financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points 0 patient safety in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation

In order to claim MOC points, users must complete the following steps:

Step 1: Review and successfully complete the activity

Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth

Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This educational activity is supported by independent medical educational grants from AstraZeneca and Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Activity Details

Accredited By

Target Audience

This activity is intended for oncologists, pulmonologists, pathologists, advanced practice nurses, nurse practitioners, and PAs who manage patients with SCLC.

Learning Objectives

• Describe the role of the immune system in tumor pathogenesis and how immunotherapy can be utilized to modulate the anti-tumor immune response
• Evaluate current and emerging immunotherapies for the management of small cell lung cancer (SCLC) on the basis of clinical trial safety and efficacy data
• Incorporate immunotherapy into the management of patients with SCLC where appropriate
• Identify and manage immune-related adverse events associated with checkpoint inhibitors

Activity Description

In this interactive panel discussion, oncology experts and a patient with SCLC discuss recent advances in the use of immunotherapy for SCLC management. Experts present the latest efficacy data supporting the use of immune checkpoint inhibitors and strategies for managing treatment-related adverse events. An experienced patient with SCLC provides his unique perspective on treatment administration, education, and expectations. The panel concludes by addressing the personalized selection of patients with SCLC who may benefit from immunotherapy.

Statement of Educational Need

Small cell lung cancer is an aggressive form of lung cancer that is historically associated with limited treatment options and low survival rates. However, in the last few years immunotherapies have emerged as effective treatment options for SCLC, particularly in people with extensive-stage disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the efficacy, safety, and tolerability of immunotherapies, the rationale for use in SCLC, and how to incorporate these treatments into SCLC management.

Agenda

This activity will address the following topics:

• Role of the immune system in tumor pathogenesis
• Rationale for immunotherapy in SCLC
• Brief overview of the mechanism of action of immunotherapy
• Evidence on the safety and efficacy of approved and emerging immune checkpoint inhibitors
• Recognizing and managing immune-mediated adverse reactions associated with immunotherapy
• Description of ongoing and planned clinical trials of immunotherapy for SCLC
• Identifying patients who may benefit from immunotherapy

Faculty

Hossein Borghaei, DO, MS (Chair)
Chief, Thoracic Oncology
Professor, Department of Hematology and Oncology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M. Dunn Chair in Thoracic Malignancies
Fox Chase Cancer Center
Philadelphia, PA

Hossein Borghaei, DO, MS, is the chief of Thoracic Oncology and a professor in the Department of Hematology/Oncology at the Fox Chase Cancer Center in Philadelphia, PA. He earned his medical degree at Philadelphia College of Osteopathic Medicine and completed his residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer. Dr. Borghaei is board certified in medical oncology.

Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic. He served as the PI of a Phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting.

Dr. Borghaei is a member of the thoracic core committee at Eastern Cooperative Oncology Group (ECOG) and, until recently, was a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer panel. He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. Dr. Borghaei is a long-standing member of ASCO, AACR, and NCCN and ECOG thoracic committees. Dr. Borghaei has published in many peer-reviewed publications, including The New England Journal of Medicine, The Lancet Oncology, Lung Cancer, and the Journal of Thoracic Oncology.

Hossein Borghaei, DO, MS, has affiliations with AbbVie, Amgen, AstraZeneca, Axiom, Boehringer Ingelheim, BioNTech, Bristol-Myers Squibb, Cantargia AB, Celgene, Daiichi, EMD-Serono, Genentech, Genmab, GLG, Huya Bio, Lilly, Merck, Novartis, Pfizer, PharmaMar, Regeneron, Takeda (Consultant); Merck/Celgene, Millennium, Bristol-Myers Squibb/Lilly (To Institution) (Contracted Research); Incyte, Takeda, U of Pennsylvania (Data Safety Monitoring Board); Rgenix, Sonnetbio (Stock).

Taofeek K. Owonikoko, MD, PhD, MSCR
Professor and Vice-Chair, Faculty Development
Department of Hematology and Medical Oncology
Chair, Thoracic Malignancies Working Group
Director of Thoracic Oncology
Co-Leader, Discovery & Developmental Therapeutics Program
Winship Cancer Institute
Emory University
Druid Hills, GA

Taofeek K. Owonikoko, MD, PhD, MSCR, is Professor and Vice-Chair for Faculty Development in the Department of Hematology and Medical Oncology and Co-Leader of the Discovery & Developmental Therapeutics Program at the Winship Cancer Institute of Emory University. Dr. Owonikoko received his primary medical training at the Obafemi Awolowo University in Ile-Ife, Nigeria. He completed his residency in anatomic pathology at the Lagos University Teaching Hospital and later proceeded to Dusseldorf, Germany for further training in anatomic pathology at the Heinrich Heine University. He received his PhD degree in anatomic pathology from the Heinrich Heine University, after which he proceeded to the Johns Hopkins University in Baltimore for postdoctoral training in molecular imaging. Dr. Owonikoko is board certified in medical oncology.

Dr. Owonikoko is a world-renowned expert in the treatment of lung cancer. He is particularly interested in advancing the care of and improving the outcomes for small cell lung cancer (SCLC). He leads an active clinical and research program at the Winship Cancer Institute at Emory University looking at new treatment strategies for patients through clinical trials and translational research work in the lab. Dr. Owonikoko has received awards on his leadership, including the IASLC Heine H. Hansen Lectureship Award and the NCI Cancer Clinical Investigator Team Leadership Award. He has also been published in many peer-reviewed journals, including the Journal of Thoracic Oncology, The Cancer Journal, Clinical Cancer Research, and Molecular Oncology.

Taofeek Owonikoko, MD, PhD, MSCR, has affiliations with AbbVie, Amgen, ARMO BioScience, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, EMD Serono, G1 Therapeutics, Heron Pharmaceutical, Lilly, MedImmune, Merck, Novartis, Sandoz, Seattle Genetics, PharmaMar, Takeda, XCovery (Consulting/Advisory Board); AbbVie, Aeglea Biotherapeutics, Amgen, Astellas Pharma, AstraZenea/MedImmune, Bayer, Bristol-Myers Squibb, Corvus Pharmaceuticals, Fujifilm, G1 Therapeutics, Incyte, Loxo/Lilly, Merck, Novartis, Pfizer, Regeneron, StemCentRx, United Therapeutics, EMD Serono, Roche/Genentech (IRC/DSMB); Cambium Oncology (Stock).

Kristen Kreamer, CRNP, AOCNP, APRN, BC
Nurse Practitioner, Thoracic and Head and Neck Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Kristen Kreamer, CRNP, AOCNP, APRN, BC, is a medical oncology nurse practitioner at Fox Chase Cancer Center in Philadelphia, PA. Ms. Kreamer earned her MS in nursing from Yale University in New Haven, CT, and worked as a clinical nurse specialist for 12 years before completing a post-masters certification as an oncology nurse practitioner at the University of Pennsylvania in Philadelphia, PA.

Ms. Kreamer’s practice includes patients with lung and head and neck malignancies and she also works with the Lung Cancer Screening and Tobacco Treatment programs at Fox Chase. She is a member of the Oncology Nursing Society, the Advanced Practice Society for Hematology/Oncology and Sigma Theta Tau International. Ms. Kreamer has been published in The Journal for Advanced Practitioners in Oncology and other peer-reviewed publications.

Kristen Kreamer, CRNP, AOCNP, APRN, BC, has affiliations with AstraZeneca (Speakers Bureau).

Cedric White (Patient)
Cedric White has nothing to disclose.

Conflict of Interest Policy/Disclosure Statement

AKH planners and reviewers have no financial relationships to disclose.
RMEI Medical Education, LLC planners and managers have no financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points 0 patient safety in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation

In order to claim MOC points, users must complete the following steps:

Step 1: Review and successfully complete the activity

Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth

Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This educational activity is supported by independent medical educational grants from AstraZeneca and Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.